Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1862-1868

  Boeckx, N ^a,b   Koukakis, R ^c   de Beeck, K Op ^a,b   Rolfo, C ^a,b   Van Camp, G ^b   Siena, S ^d,e   Tabernero, J ^f   Douillard, J Y ^g   Andre T ^h   Peeters, Marc ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c AMGEN LTD   (United Kingdom)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UMR INSERM U892 CNRS 6299   (France)

^h HÔPITAL SAINT ANTOINE   (France)

Author keywords

First line; Metastatic colorectal cancer; Panitumumab; RAS wild type; Tumor sidedness

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE RAS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; WILD TYPE; COLORECTAL TUMOR; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85029304294     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx119     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
2. Welch HG, Robertson DJ. Colorectal cancer on the decline-why screening can't explain it all. N Engl J Med 2016; 374: 1605-1607
3. Heinemann V, Rivera F, O'Neil BH et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wildtype metastatic colorectal cancer. Eur J Cancer 2016; 67: 11-20
4. Holch J, Stintzing S, Heinemann V. Treatment of metastatic colorectal cancer: standard of care and future perspectives. Visc Med 2016; 32: 178-183
5. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer 2017; https://www.nccn. org/ (30 March 2017, date last accessed)
7. Sartore-Bianchi A, Trusolino L, Martino C et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/ 13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746
8. Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 2015; 6: 660-667
9. Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594
10. Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
11. Lee GH, Malietzis G, Askari A et al. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol 2015; 41: 300-308
12. Benedix F, Kube R, Meyer F et al. Comparison of 17,641 patients with right-and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53: 57-64
13. Benedix F, Schmidt U, Mroczkowski P et al. Colon carcinoma-classification into right and left sided cancer or according to colonic subsite? Analysis of 29,568 patients. Eur J Surg Oncol 2011; 37: 134-139
14. Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001
15. Tejpar S, Stintzing S, Ciardiello F et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017; 3: 194-201
16. Ciardiello F, Lenz H, Peeters M et al. Right or left metastatic colorectal cancer: will the side change your treatment? Special Session at the ESMO 2016 Congress, Copenhagen, Denmark; 10 October 11:15-12:50; http:// www.esmo.org/Conferences/ESMO-2016-Congress/Webcasts/ (30 March 2017, date last accessed)
17. Venook AP, Niedzwiecki D, Innocenti F et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34(Suppl): abstr 3504. http://meetingli brary.asco.org/content/161936-176/ (30 March 2017, date last accessed)
18. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705
19. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wildtype KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32: 2240-2247
20. Rivera F, Karthaus M, Hecht JR et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC). Ann Oncol 2015; 26(suppl_4): iv105. https://doi.org/10.1093/ annonc/mdv234.13/ (30 March 2017, date last accessed)
21. Loupakis F, Yang D, Yau L et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107: dju427. https://doi.org/10.1093/jnci/dju427/ (30 March 2017, date last accessed)
22. Petrelli F, Tomasello G, Borgonovo K et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and metaanalysis. JAMA Oncol 2017; 3: 211-219
23. von Einem JC, Heinemann V, von Weikersthal LF et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140: 1607-1614
24. Pai RK, Jayachandran P, Koong AC et al. BRAF-mutated, microsatellitestable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36: 744-752
25. Heinemann V, Modest DP, von Weikersthal LF et al. Gender and tumor location as predictors for efficacy: influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014; 32(suppl): abstr 3600. http://meetinglibrary.asco.org/content/131993-144/ (30 March 2017, date last accessed)
26. Lee MS, Advani SM, Morris J et al. Association of primary site and molecular features with prgression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy. J Clin Oncol 2016; 34(suppl): abstr 3506 http://meetinglibrary. asco.org/content/171167-176/ (30 March 2017, date last accessed)